AI & ChatGPT searches , social queries for RINTODESTRANT
Search references for RINTODESTRANT. Phrases containing RINTODESTRANT
See searches and references containing RINTODESTRANT!
Search references for RINTODESTRANT. Phrases containing RINTODESTRANT
See searches and references containing RINTODESTRANT!RINTODESTRANT
Chemical compound
Rintodestrant (G1T48) is an orally bioavailable selective estrogen receptor degrader (SERD) discovered in Greg Thatcher's lab at UIC and developed by
Rintodestrant
Pharmaceutical company
bladder cancer who are receiving chemotherapy followed by avelumab. Rintodestrant, an oral selective estrogen receptor degrader (SERD), is being developed
G1_Therapeutics
Class of drugs
Sanofi in the lead". Evaluate.com. 2020-02-19. Retrieved 2020-12-28. "Rintodestrant | oral selective estrogen receptor degrader (SERD) | G1 Therapeutics
Selective estrogen receptor degrader
Selective_estrogen_receptor_degrader
estrogen receptor degrader for breast cancer and endometrial cancer Rintodestrant (G1T-48) – selective estrogen receptor modulator and selective estrogen
List of investigational sex-hormonal agents
List_of_investigational_sex-hormonal_agents
Medication for HR+ HER2– breast cancer
ER+/HER2- breast cancer. Studies include palbociclib plus G1 Therapeutic's rintodestrant and Zentalis's Zn-c5. Palbociclib has several direct competitors currently
Palbociclib
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT
RINTODESTRANT